Affimed Income After Taxes 2014-2024 | AFMDQ
Affimed income after taxes from 2014 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Affimed Annual Income After Taxes
(Millions of US $) |
| 2023 |
$-115 |
| 2022 |
$-91 |
| 2021 |
$-68 |
| 2020 |
$-47 |
| 2019 |
$-36 |
| 2018 |
$-23 |
| 2017 |
$-34 |
| 2016 |
$-36 |
| 2015 |
$-22 |
| 2014 |
$0 |
| 2013 |
$7 |
| 2012 |
$2 |
Affimed Quarterly Income After Taxes
(Millions of US $) |
| 2024-09-30 |
$-17 |
| 2024-06-30 |
$-17 |
| 2024-03-31 |
$-21 |
| 2023-12-31 |
$-22 |
| 2023-09-30 |
$-27 |
| 2023-06-30 |
$-32 |
| 2023-03-31 |
$-34 |
| 2022-12-31 |
$-35 |
| 2022-09-30 |
$-17 |
| 2022-06-30 |
$-21 |
| 2022-03-31 |
$-19 |
| 2021-12-31 |
$-27 |
| 2021-09-30 |
$-20 |
| 2021-06-30 |
$-23 |
| 2021-03-31 |
$2 |
| 2020-12-31 |
$-18 |
| 2020-09-30 |
$-7 |
| 2020-06-30 |
$-13 |
| 2020-03-31 |
$-9 |
| 2019-12-31 |
$-15 |
| 2019-09-30 |
$-12 |
| 2019-06-30 |
$-12 |
| 2019-03-31 |
$2 |
| 2018-12-31 |
$11 |
| 2018-09-30 |
$-14 |
| 2018-06-30 |
$-10 |
| 2018-03-31 |
$-10 |
| 2017-12-31 |
$-8 |
| 2017-09-30 |
$-10 |
| 2017-06-30 |
$-9 |
| 2017-03-31 |
$-8 |
| 2016-12-31 |
$-6 |
| 2016-09-30 |
$-11 |
| 2016-06-30 |
$-9 |
| 2016-03-31 |
$-9 |
| 2015-12-31 |
$-7 |
| 2015-09-30 |
$-8 |
| 2015-06-30 |
$-6 |
| 2015-03-31 |
$-2 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$10 |
| 2014-06-30 |
$1 |
| 2014-03-31 |
$1 |
| 2013-09-30 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.001B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
